Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
<p><strong>Background:</strong> Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellen...
主要な著者: | Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
BioMed Central
2023
|
類似資料
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
著者:: Ezgi Ozyerli-Goknar, 等
出版事項: (2023-11-01) -
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
著者:: Yedier-Bayram, O, 等
出版事項: (2022) -
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
著者:: Ozyerli-Goknar, E, 等
出版事項: (2019) -
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
著者:: Saraç, H, 等
出版事項: (2019) -
Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
著者:: Filiz Senbabaoglu, 等
出版事項: (2020-12-01)